No abstract available.
Herpesviridae* ; Herpesvirus 7, Human ; Herpesvirus 8, Human ; Humans*

No abstract available.
Biopsy* ; Herpesvirus 8, Human ; Sarcoma, Kaposi*

Castleman's disease (CD) is a rare lymphoproliferative disorder that comprises at least two distinct clinical subtypes (unicentric and multicentric). Three pathologic variants (hyaline vascular variant, plasma cell variant, and mixed variant) have been recognized. In addition to interleukin-6 and human herpes virus 8, some other cytokines and viruses may also be involved in the pathogenesis of CD. This review summarizes the recent advances in the underlying pathogenesis of CD, with an attempt to provide evidence for new treatment options that may change the current treatment strategies and improve patients' outcomes.
Castleman Disease ; Herpesvirus 8, Human ; Humans ; Interleukin-6

Kaposi sarcoma (KS) is an angioproliferative tumor affecting the blood and lymphatic vessels. The human herpesvirus 8 (HHV8) is directly implicated in the development of the disease. Non-AIDS kaposi sarcoma is a rare clinical type of KS and must be distinguished from AIDS-associated KS as it differs in clinical presentation, course, prognosis, and management.

A 73-year old male, Filipino, rice farmer, from Quezon Province, Philippines, presented with a progressive 10-year history of violaceous to hyperpigmented plaques and nodules on all extremities, with associated pruritus and difficulty in performing fine motor tasks. Histopathology showed proliferation of vascular channels and immunohistochemical stains were positive for CD31, CD34, and human herpesvirus 8 (HHV8), consistent with KS. Work-up revealed non-reactive HIV serology with an adequate CD4 count and computed tomography (CT) scan of the chest and abdomen were unremarkable. The case was classified as non-AIDS KS. He was then referred to oncology for chemotherapy with paclitaxel.

This case highlights that KS can occur in non-endemic areas and in immunocompetent individuals. Non-AIDS KS must be differentiated from other types of KS since non-AIDS KS is less aggressive, limited to the skin, and is highly responsive to therapy. It is therefore crucial to correlate clinical and histopathologic findings, utilizing immunohistochemical stains, as histology of KS can mimic benign vascular tumors, and it is crucial to achieve an early and accurate diagnosis. There are currently no treatment guidelines for KS and management aims to decrease morbidity and improve a patient’s quality of life.

BACKGROUND: The differential diagnosis of Kaposi sarcoma includes many disease that range from benign disease to malignant tumors. However, little information is available about the immunohistochemical characteristics of Kaposi sarcoma. METHODS: The expressions of 13 various proteins (HHV-8 LNA-1, Ki-67, bcl-2, p53, CD31, CD34, factor VIII, D2-40, vimentin, SMA, S-100, EMA, and c-kit) were evaluated immunohistochemically in 49 vascular tumors including 16 Kaposi sarcomas, 8 angiosarcomas, 2 hemangioendotheliomas, and 23 benign vascular tumors with using the tissue array method. RESULTS: All 16 cases of Kaposi sarcoma showed nuclear staining for HHV-8 LNA-1, whereas all the cases of angiosarcoma and benign vascular lesions were negative for HHV-8 LNA-1 (p<0.001). All Kaposi sarcoma were positive for D2-40, which is a marker of lymphatic differentiation, but 25% of the benign vascular lesions and 30.4% of the angiosarcoma were positive for D2-40 (p<0.001). The mean proliferation index as assessed by Ki-67 immunostaining revealed no difference between the benign and malignant vascular lesions (p>0.05). No Kaposi sarcoma showed a bcl-2 expression, but 62.5% of the angiosarcomas and 21.7% of the benign vascular tumors had bcl-2 expressions (p=0.005). CONCLUSIONS: Immunohistochemical detection of HHV-8 LNA-1 and D2-40 are useful tools to differentiate Kaposi sarcoma from other vascular tumors.
Diagnosis, Differential ; Factor VIII ; Hemangioendothelioma ; Hemangiosarcoma ; Herpesvirus 8, Human ; Immunohistochemistry ; Sarcoma, Kaposi* ; Vimentin

Castleman's disease is a rare atypical lymphoproliferative disorder. Although HHV-8 has been reported to be a cause of Castleman's disease, the etiology and pathogenesis of the disease remains mostly unknown. We experienced a 51-year-old female patient who was concurrently diagnosed with Castleman's disease and systemic lupus erythematosus. Castleman's disease has been rarely reported in patients with systemic lupus erythematosus. Thus, we report the case and briefly discuss relevant articles.
Female ; Giant Lymph Node Hyperplasia ; Herpesvirus 8, Human ; Humans ; Lupus Erythematosus, Systemic ; Lymphoproliferative Disorders

No abstract available.
Herpesvirus 8, Human* ; Humans* ; Kidney Transplantation ; Lymphohistiocytosis, Hemophagocytic* ; Sarcoma, Kaposi* ; Transplant Recipients*

Kaposi's sarcoma(KS) occurs in four distinct subsets: classic, African-endemic, iatrogenic immunosuppressive drug-associated, and AIDS-associated KS. Only two cases of AIDS-associated KS have been reported in Korea. The pathogenesis remains unclear but, suggested the relevance to the association of virus infection with KS, especially human herpesvirus-8. We report a case of an AIDS-related KS that human herpesvirus-8 DNA is present in the KS tissue. The patient was diagnosed with AIDS in 1993 and had complained of disseminated erythematous to purplish colored papulonodules on the face, neck, chest and back for 5months. He was treated with systemic cytotoxic chemotherapy, but died due to septic condition.
DNA ; Drug Therapy ; Herpesvirus 8, Human ; Humans ; Korea ; Neck ; Sarcoma, Kaposi* ; Thorax

Antiviral Agents ; pharmacology ; therapeutic use ; Drug Design ; Herpesvirus 8, Human ; drug effects ; Humans ; Simplexvirus ; drug effects

Castleman's disease (CD) is a rare lymphoproliferative disorder. The etiology of CD may involve viral infection, abnormal modulation of cytokines, and angiogenesis. Human herpes virus (HHV) -8 infection and interleukin-6 (IL-6) overexpression may play key roles in the development of CD. Treatment options include surgical excision, radiation therapy, chemotherapy, antiviral therapy, and targeted therapy. No standardized treatment has been established for multicentric CD and the treatment efficacy usually is poor. Among newly available agents, the effectiveness of antiviral therapy against HHV-8 is unclear; anti-CD20 and anti-IL-6 receptor monoclonal antibodies have shown promising efficacy; thalidomide and bortezomib have shown their initial efficacy.
Castleman Disease ; etiology ; metabolism ; therapy ; Herpesvirus 8, Human ; Humans ; Interleukin-6 ; metabolism